Summary Points 46
• Health disparities persist across race/ethnicity for the majority of Healthy People 47 2010 health indicators. 48
• Most physicians and scientists are informed by research extrapolated from a 49 largely homogenous population, usually White and male. 50
• A growing proportion of Americans are not fully benefiting from clinical and 51 biomedical advances since racial and ethnic minorities make up nearly 40% of 52 the U.S. population. 53
• Ignoring the racial/ethnic diversity of the U.S. population is a missed scientific 54 opportunity to fully understand the factors that lead to disease or health. 55
• U.S. biomedical research and study populations must better reflect the country's 56 changing demographics. Adequate representation of diverse populations in 57 scientific research is imperative as a matter of social justice, economics, and 58 science. 59
In 1993, the National Institutes of Health (NIH) Revitalization Act was passed by United 60
States (U.S.) Congress and signed into law by President Clinton [1] . The Act called for 61 the NIH to require that all federally-funded clinical research prioritize the inclusion of 62 women and minorities and that research participant characteristics be disclosed in 63 research documentation [1] . When pivotal NIH-funded studies included large 64 proportions of women by design, they made important, clinically relevant scientific 65 contributions by identifying sex-specific differences in symptoms, pathologies, and 66 treatment response [2] [3] [4] . In continuation of this effort, the NIH announced new 67 measures to enhance gender equity [5] . Herein, we evaluate the impact of the 68 Revitalization Act's other stated aim: diversifying study populations by race/ethnicity. 69
We also make suggestions on what we believe will bolster the Revitalization Act's effect 70 in shaping clinical and biomedical research and thereby provide guidance for President 71
Obama's new Precision Medicine Initiative (PMI) [6] . 72
Disease pattern, clinical presentation, and therapeutic response can vary 73 dramatically by race/ethnicity and ancestral background 74
Race is a social construct rooted in cultural identity and shaped by historic and current 75 events, which influence an individual's behavior and place of residence. Genetic 76 variation correlates with self-identified race [7] , and this genetic variation also 77 correlates with clinical presentation and therapeutic response. Thus, while not every 78 study needs to examine racial differences or include all racial/ethnic groups, we feel that 79 the group(s) included should be representative of their larger population(s) such that 80
including an adequate proportion of racially/ethnically diverse groups in clinical and 81 biomedical research can provide meaningful opportunities to examine the complex 82 relationship of ancestral influences, environmental exposures, and social factors. In 83 turn, understanding the interaction between the social and environmental milieu with 84 an individual's genomic profile and genetic ancestry can extend our understanding of 85 disease pathology and expand therapeutic options for everyone [8] . For example, up to 86 75% of Pacific Islanders are unable to convert the antiplatelet drug clopidogrel into its 87 active form and are at higher risk for adverse outcomes following angioplasty [9, 10] .
88
Other examples are listed in Table 1 . 89 Highly feasible changes can increase minority participation despite the challenges 128 described. Ideally, investigators would reflect the communities being studied. Given the 129 tremendous disparities in our biomedical workforce, we must seek out other realistic 130 solutions. For example, some participants prefer studies that include research staff who 131 share their same culture and with whom they can communicate in their own language 132
[31]. Potential contributors are also more likely to partake when recruited by research 133 staff they personally know or with whom they identify [33, 34] . Town hall meetings and 134 study newsletters can be adapted to the language and reading level requirements of 135 target groups; these can describe how collected data will be used, ensuring transparency 136 and allaying fears stemming from lack of information [29]. Challenges of transportation, 137 childcare, work hour considerations, and meals can be addressed via payment, travel 138 support, flexible recruitment hours and locations, provision of food during study visits, 139 and positioning study sites in areas with diverse residents. To compensate for the 140 limited internal referral base, tertiary care centers can partner with community 141 healthcare providers. Targeted advertising (e.g., on public transportation) can reach 142 potential participants at a moderate cost. Nonetheless, outreach and external 143 partnerships introduce costs and effort that can raise recruitment budgets. The 144
Revitalization Act specifically prohibits cost considerations from being a reason to 145 exclude minorities, and NIH study sections are instructed to disregard budgetary 146 requests in evaluating a project's scientific merit. However, our experience in grant 147 reviewing has been that in practice, the size of budgetary requests can bias reviewers. 148
Grant applicants, in turn, react by submitting proposals with inadequate budgets to 149 recruit minority participants so as not to "raise eyebrows" of reviewers. 150
Minorities would likely to be as willing to be involved in research as whites if problems 151 of diversity could be better addressed. Some of these problems may stem from issues 152 within the research community and its own profound diversity gap. Minority physicians 153 and scientists are more likely to conduct research in minority populations and are often 154 best suited to gain the trust of minority communities, but they are also significantly 155 To further complicate the picture, an NIH study of research grant awards found that the 164 proportion of applications funded was 13% lower for Blacks or African Americans and 165 4% lower for Asians than among Whites [39] . According to demographic information 166 provided by the NIH's Office of Extramural Research under the Freedom of Information 167 Act, the award rate for R01 or equivalent grants has been consistently lower among non-168
White applicants (Pacific Islander, Native Hawaiian, African American, American 169 Indian, and Asian) than White applicants (42.1% versus 48.6% in 1985 and 19.3% versus 170 23.3% in 2013) [40] . 171
Contributors to funding disparities arise throughout the research application review 172 process [41] . The NIH has commented on reviewer bias [42] , acknowledging that the 173 probability of funding after peer review does not differ by race, but that minority 174 investigators tend to receive lower priority scores from peer review, indicating that the 175 review process is biased against applications from minority investigators. The relative 176 absence of minority participants throughout the research application evaluation process 177 may contribute to this problem, since underrepresented minorities comprised 10% of 178 To their credit, the NIH is actively addressing many of the issues we have mentioned. 209
Following President Obama's PMI announcement during his 2015 State of the Union 210 address, the NIH has actively solicited feedback [46] to help guide creation of a diverse 211 research cohort of 1 million or more Americans [47] . The NIH has since hosted several 212 workshops to develop a vision for building the national PMI cohort, and maximizing 213 cohort diversity (across socioeconomic standing, geography, sexual orientation, 214 education, and age, in addition to race/ethnicity) has been an ongoing topic at these 215 workshops [48] . In particular, participant and public engagement, diversity and 216 inclusion, and health disparities considerations for the development of a national 217 research cohort were among the topics discussed at a workshop dedicated to participant 218 engagement and health equity [49] . 219
We applaud and encourage the NIH's focus on diversifying the makeup of the 220 forthcoming PMI cohort. To build on these efforts, an administrative supplement for 221 currently funded research to investigate racial/ethnic differences in health and 222 therapeutics should be created, similar to efforts by the Office of Research on Women's 223
Health to promote discovery of sex differences [50] . This supplement would be 224 hypothesis-generating and show the NIH's commitment to diversify study populations 225 throughout all Institutes. The NIH should also incentivize collaboration amongst groups 226 with similar approaches and data elements so that adequately powered analyses can 227 examine racial/ethnic differences. 228
Applications from minority-serving institutions should be judged on their capacity to 229 conduct research rather than relying on the institutions' research track records. In our 230 experience, applications from institutions with strong community ties are better 231 equipped to enroll and retain subjects in clinical and biomedical research. The 232 importance and novelty of studies focused primarily or solely on minority populations 233 should be recognized for their validity and worth, as these may be the only studies to 234 recruit sufficient minority participants to determine whether research findings can be 235 generalized to these populations. 236
Given the systemic bias against minority scientists, the solution does not lie in simply 237 increasing the number of competitive applicants. To this end, the NIH is actively 238 funding investigations to understand and eliminate discrepancies for minority 239 investigators in the peer review process [51] . In September 2014, the NIH announced 240
[52] winners of two competitions on increasing the fairness and impartiality of the 241 scientific review process and for novel methods of identifying bias. A program assessing 242 the complete anonymization of grant applications is also being piloted [53]. These 243 efforts are part of a larger campaign to identify and root out unconscious bias in peer 244 review [41, 51] . The NIH must act on these data to ensure a just and fair voice for all 245 stakeholders. 246 NIH proposals passing scientific peer review are forwarded to a second level of review, 247 conducted by Institute and Center (IC) National Advisory Councils or Boards 248 (henceforth referred to as "Councils"). NIH Councils make funding decisions based on 249 the priority score and the priorities of the IC, which have varying levels of discretionary 250 funds. A reasonable way to fund meritorious applications that reflect the diversity 251 priorities of the ICs is to use the discretion of the Councils. Other NIH efforts to increase 252 support for the diversity pipeline (e.g., BUILD [54]) and for diversity-related scientific 253 initiatives are commendable, but in the absence of strong changes throughout the 254 review process, research will continue to suffer. 255
Inclusive research needs the support of the entire country 256
Efforts by the NIH and other agencies to address disparities in research priorities will 257 have limited impact unless broader themes of political and economic inequality are 258 addressed. The most important changes in our approach to science will only come when 259 we consider inclusion and diversity important by default-not just in biomedical 260 science, but in all aspects of society. Homogeneity in study populations will cease when 261 racial/ethnic and socioeconomic diversity are considered socially desirable and social 262 norms [55], be it in study populations, academic faculty, NIH study sections, or 263 boardrooms and classrooms. 264
We have suggested a number of measures for the NIH to build upon the Revitalization 265 Act. Despite the Act's stipulation that cost not be used as justification for failure to 266 enroll diverse populations, no discussion of new mandates for NIH-funded research can 267 take place without addressing the crisis of declining inflation-adjusted NIH budgets. 268
Society and patients will benefit when the NIH exercises the full scope of power 269 provided under the 1993 Act: a call for the inclusion of historically under-represented 270 communities in clinical research. The NIH alone will not be able to correct the 271 disparities or inequities of the healthcare system, but it can send a powerful message 272 that may promote changes in our health care and health science systems. There must be 273 a collective will to prioritize diversifying our study populations, rallied by outreach to 274 the lay community to educate voters who can exercise their franchise to their own best 275 healthcare interests. 276
Fulfilling the promise of the Revitalization Act does not pit a future of precision 277 medicine and the advancement of science against the realization of social justice for 278 under-represented communities. Rather, the choice to study diverse populations is itself 279 a promising path toward sound science. By reprioritizing our approach to clinical 280 research and recruitment, we may accomplish an even greater goal: to usher in a new 281 era of scientific discovery and health prosperity for all citizens of the world. 282
